Last reviewed 2026-05-20 · How we verify

Evoximab

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Phase 2 active Small molecule ✓ Verified May 2026

Evoximab is a Small molecule drug developed by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. It is currently in Phase 2 development. Also known as: AK112.

Evoximab (AK112) is being studied in combination with stereotactic radiotherapy and chemotherapy (pemetrexed) as a new adjuvant therapy for stage II-III non-small cell lung cancer. This treatment is being investigated in a clinical trial (NCT06391008) at The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Evoximab
Also known as	AK112
Sponsor	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Evoximab CI brief — competitive landscape report
Evoximab updates RSS · CI watch RSS
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School portfolio CI

Frequently asked questions about Evoximab

What is Evoximab?

Evoximab is a Small molecule drug developed by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School.

Who makes Evoximab?

Evoximab is developed by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (see full The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School pipeline at /company/the-affiliated-nanjing-drum-tower-hospital-of-nanjing-university-medical-school).

Is Evoximab also known as anything else?

Evoximab is also known as AK112.

What development phase is Evoximab in?

Evoximab is in Phase 2.

Manufacturer: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School — full pipeline
Therapeutic area: All drugs in Other
Also known as: AK112

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing